GSK-580416

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameGSK-580416
Drug Alias NameGSK-580416580416
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRibosomal proteins inhibitorsTopoisomerase II inhibitors
TargetsRibosomal proteinsTopoisomerase II
Therapy Area/IndicationsRespiratory Tract InfectionsBacterial Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsRespiratory Tract InfectionsBacterial Infections

Other Information

ATC CodeN/A
Related LinksN/A